Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Index Rebalance

<ul>
<li>In this insight, I provide an early look at the potential additions and deletions to KOSDAQ150 rebalance in December 2026.</li>
<li>I provide 9 potential deletion candidates including C&amp;C International Corp (352480 KS), Devsisters (194480 KS), and Webzen Inc (069080 KS). </li>
<li>The 7 potential addition candidates include Mezzion Pharma (140410 KS), Taihan Fiberoptics (010170 KS), and Seers (458870 KS). </li>
</ul>


In this insight, I provide an early look at the potential additions and deletions to KOSDAQ150 rebalance in December 2026.
I provide 9 potential deletion candidates including C&amp;C International Corp (352480 KS), Devsisters (194480 KS), and Webzen Inc (069080 KS). 
The 7 potential addition candidates include Mezzion Pharma (140410 KS), Taihan Fiberoptics (010170 KS), and Seers (458870 KS). 


An Early Look at the Potential KOSDAQ150 Rebalance Candidates in December 2026

Equity Bottom-Up

<ul>
<li>Seers (458870 KS) is a digital healthcare firm in Korea that specializes in wearable medical biosensors, artificial intelligence (AI)-driven clinical data analysis, and remote patient monitoring (RPM) platforms.</li>
<li>Given the company's surging sales and profit growth, I believe it deserves to trade at 20x P/E. </li>
<li>Assuming consensus net profit estimate of 86.8 billion won, a 20X P/E suggests market cap of 1.7 trillion won, representing 110% upside from current levels (about 44,000 won per share). </li>
</ul>


Seers (458870 KS) is a digital healthcare firm in Korea that specializes in wearable medical biosensors, artificial intelligence (AI)-driven clinical data analysis, and remote patient monitoring (RPM) platforms.
Given the company's surging sales and profit growth, I believe it deserves to trade at 20x P/E. 
Assuming consensus net profit estimate of 86.8 billion won, a 20X P/E suggests market cap of 1.7 trillion won, representing 110% upside from current levels (about 44,000 won per share). 


<ul>
<li>Mezoo, which provides wearable medical devices and software, is experiencing exploding sales and profit growth. </li>
<li>Mejoo generated sales of 9.6 billion won (up 216% YoY) in 1H 2026. Operating margin improved materially from -47.5% in 1H 2025 to 19.1% in 1H 2026.</li>
<li>Despite surging sales and profits, valuations are dirt cheap. It is trading at P/E of 5.4x based on 2027 consensus earnings estimates.</li>
</ul>


Mezoo, which provides wearable medical devices and software, is experiencing exploding sales and profit growth. 
Mejoo generated sales of 9.6 billion won (up 216% YoY) in 1H 2026. Operating margin improved materially from -47.5% in 1H 2025 to 19.1% in 1H 2026.
Despite surging sales and profits, valuations are dirt cheap. It is trading at P/E of 5.4x based on 2027 consensus earnings estimates.


South Korea

SEERS Co., Ltd. develops and manufactures medical equipment. The Company produces holter electrocardiograph devices, pulse oximeters, and other products. SEERS conducts businesses in South Korea.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Seers (458870 KS)

An Early Look at the Potential KOSDAQ150 Rebalance Candidates in December 2026

In this insight, I provide an early look at the potential additions and deletions to KOSDAQ150 rebalance in December 2026.

Douglas Kim

Korea Small Cap Gem #68: Seers Co

Seers is a digital healthcare firm in Korea that specializes in wearable medical biosensors, artificial intelligence (AI)-driven clinical data...

Douglas Kim

Korea Small Cap Gem #69: Mezoo

Mezoo, which provides wearable medical devices and software, is experiencing exploding sales and profit growth. Despite surging sales and profits,...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)